In vitro evidence of HER2-selective cytotoxicity by scFv(Herceptin)-PE-STXA immunotoxin in gastric cancer cells

The delivery of therapeutic agents in a targeted manner shows great potential for improving the degree of efficacy in cancer therapies by minimizing harm for normal tissues and reducing treatment-related complications. Among patients with gastric cancer, the HER2 receptor is expressed in approximate...

書目詳細資料
發表在:	Biochemistry and Biophysics Reports
Main Authors:	Hamid Sedighian, Arash Abdi, Zoleikha Goleij, Mahdi Fasihi-Ramandi, Abbas Ali Imani Fooladi
格式:	Article
語言:	英语
出版:	Elsevier 2025-09-01
主題:	HER2 Gastric cancer Apoptosis Herceptin Targeted cancer immunotherapy
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S240558082500305X

相似書籍

Design of a Humanized Immunotoxin Based on Pertuzumab-Derived scFv and Shiga-Like Toxin 2 Subunit A Against Breast Cancer: An In Silico Study
由: Zeinab Ghesmati, et al.
出版: (2025-05-01)

Damaging non-synonymous mutations in the extracellular domain of HER2 potentially alter the efficacy of Herceptin-mediated breast cancer therapy
由: Arijit Samanta, et al.
出版: (2025-09-01)

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
由: Brenen P. Swofford, et al.
出版: (2017-12-01)

Mild hyperthermia influence on Herceptin® properties
由: Escoffre Jean-Michel, et al.
出版: (2015-03-01)

Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients
由: Yu Song, et al.
出版: (2024-12-01)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
由: Florence R. Wilson, et al.
出版: (2017-10-01)

Target therapy in treatment of HER2-positive breast cancer
由: A. S. Belokhvostova, et al.
出版: (2016-02-01)

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2<sup>+</sup> Solid Cancer
由: Andreas A. Hombach, et al.
出版: (2023-01-01)

Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients
由: Liantao Guo, et al.
出版: (2024-01-01)

Left Ventricular Function and Echocardiographic Parameters in Patients Undergoing Chemotherapy With 5‐Fluorouracil, Anthracycline, Taxotere, and Herceptin: Prospective Cohort Study
由: Alireza Abdollahi Moghadam, et al.
出版: (2025-08-01)

Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25
由: Yanjie Peng, et al.
出版: (2023-05-01)

Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability
由: Emma L. Wilkinson, et al.
出版: (2016-10-01)

Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3)
由: Moslem Afrakhteh, et al.
出版: (2017-11-01)

Trastuzumab: updated mechanisms of action and resistance in breast cancer
由: Francois X. Claret, et al.
出版: (2012-06-01)

Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
由: Deng Lan, et al.
出版: (2023-01-01)

Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2
由: Xiao Tian, et al.
出版: (2017-10-01)

Computational analysis of fusion protein of anti-HER2 scFv and alpha luffin: A new immunotoxin protein for HER2 positive cancers
由: Farzaneh Barkhordari, et al.
出版: (2022-12-01)

Long-term follow-up of early stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real world multicenter cohort study
由: Sander Ellegård, et al.
出版: (2022-08-01)

Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering
由: Olga Bednova, et al.
出版: (2025-04-01)

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
由: Christophe Alric, et al.
出版: (2018-02-01)

scFv Antibody: Principles and Clinical Application
由: Zuhaida Asra Ahmad, et al.
出版: (2012-01-01)

Specific Detection of His-Tagged Proteins with Recombinant Anti-His Tag scFv-Phosphatase or scFv-Phage Fusions
由: P. Lindner, et al.
出版: (1997-01-01)

Discovery and in vitro characterization of a human anti-CD36 scFv
由: Cecilia Mata-Cruz, et al.
出版: (2025-02-01)

The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients
由: M Yazici, et al.
出版: (2007-10-01)

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models
由: Wu Xianhua, et al.
出版: (2012-08-01)

Mechanisms of reduced efficacy of HER2-targeted therapy in HER2-low breast cancer by long-term nicotine exposure in patient-derived xenograft mouse tumor models
由: Yu-Hsuan Lin, et al.
出版: (2025-04-01)

“Stapling” scFv for multispecific biotherapeutics of superior properties
由: Lauren E. Boucher, et al.
出版: (2023-12-01)

INCREASING OF THE EXPRESSION OF RECOMBINANT scFv-ANTIBODIES EFFICIENCY
由: O.V. Galkin, et al.
出版: (2017-10-01)

Quantum Dot- Conjugated Anti-GRP78 scFv Inhibits Cancer Growth in Mice
由: David Hornby, et al.
出版: (2012-01-01)

Synergistic HER2-scFv mediated immunotherapy with targeted gemcitabine delivery harnessing biomimetic composite nanoparticles for enhanced metastatic tumor therapy
由: Xinan Wang, et al.
出版: (2025-06-01)

Species-Dependent Functionality of the Human Cytolytic Fusion Proteins Granzyme B-H22(scFv) and H22(scFv)-Angiogenin in Macrophages
由: Theo Thepen, et al.
出版: (2013-01-01)

Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer
由: Cynthia Rodríguez-Nava, et al.
出版: (2023-06-01)

scFv biofunctionalized nanoparticles to effective and safe targeting of CEA-expressing colorectal cancer cells
由: Maria José Silveira, et al.
出版: (2023-10-01)

Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
由: Irina V. Kholodenko, et al.
出版: (2019-10-01)

Enhancing antitumor activity of herceptin in HER2-positive breast cancer cells: a novel DNMT-1 inhibitor approach
由: Li-li Ren, et al.
出版: (2024-11-01)

Engineering a cell-penetrating hyperstable antibody scFv(Ras) – An extraordinary approach to cancer therapeutics
由: Jina Bae, et al.
出版: (2021-12-01)

Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells
由: Wenhao Niu, et al.
出版: (2024-07-01)

The Four-State Equilibrium Unfolding of a scFv Antibody Fragment
由: Idolka Pedroso, et al.
出版: (2002-01-01)

Development of tularemic scFv antibody fragments using phage display
由: Kubelkova Klara, et al.
出版: (2010-06-01)

Construction, Structural Modeling of a Novel ScFv against Human Gastric Cancer from Phage-display Library
由: Lijuan Yang, et al.
出版: (2011-03-01)